Clinical trials: Blood Plasma Therapy
Cervical Intraepithelial Neoplasia Grade 2 (CIN2), Cervical Intraepithelial Neoplasia Grade 2
Evaluation of Low-thermal Argon Plasma Devitalization for the Treatment of CIN 2 Versus Standard of Active Surveillance
The study aims to show that treatment with LtAPD works better than a sham treatment or simply monitoring the condition closely without active treatment ("active surveillance"), in achieving complete healing of a tissue…
- Conditions
- Cervical Intraepithelial Neoplasia Grade 2 (CIN2), Cervical Intraepithelial Neoplasia Grade 2, CIN2
- Trial name
- CINPLASTA (NCT07730645)
- Testing
- Treatment with low-thermal argon plasma devitalization
- Where
- Germany
- Volunteers
- 264 people
- Sponsor
- University Hospital Tuebingen
Respiratory Failure, ARDS
Plasma Adsorption in Patients With Confirmed COVID-19
To characterize the ability of the D2000 Cartridge in combination with the Optia SPD Protocol to reduce the morbidity and mortality associated with SARS-CoV-2 infection in patients admitted to the ICU.
- Trial name
- NCT04358003
- Testing
- Marker Therapeutics D2000 Cartridge (D2000) for use with the Spectra Optia® Apheresis System (Optia SPD Protocol)
- Where
- 7 sites in United States
- Volunteers
- 107 people
- Sponsor
- Marker Therapeutics AG
Multiple Myeloma, Relapsed/Refractory
Testing JNJ-42756493 In Combination With Dexamethasone in Multiple Myeloma That Came Back After a Period of Improvement
This is a phase 2 study to see how effective investigational drug, JNJ-42756493, is when given in combination with dexamethasone in two groups of patients with multiple myeloma (cancer of the plasma cells, a type of white blood…
- Trial name
- NCT02952573
- Testing
- JNJ-42756493, Dexamethasone
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Knee Arthritis, Osteoarthritis
Platelet-Rich Plasma Composition and Clinical Effects in Knee Osteoarthritis
This is a prospective, observational cohort study involving 40 patients with primary knee osteoarthritis hospitalized in a rehabilitation hospital in Cluj-Napoca.
- Trial name
- NCT07558980
- Testing
- intra-articular administration of plasma rich in platelets (PRP)
- Where
- Romania
- Volunteers
- 40 people
- Sponsor
- Iuliu Hatieganu University of Medicine and Pharmacy
HIV Infections
The Addition of Indinavir to Anti-HIV Treatment in HIV-Infected Patients
The purpose of this study is to evaluate the effect of immediate versus deferred indinavir (IDV) in addition to background therapy on disease progression or death in patients with CD4+ cell counts between 200 and 500 cells/mm3…
- Trial name
- NCT00000861
- Testing
- Indinavir sulfate
- Where
- 14 sites in United States
- Volunteers
- 1,900 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Menopause, Menopause Ovarian Failure
Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation
SEGOVA procedure includes - Stem cell therapy, G - Growth factor Platelet Plasma Rich therapy and in Vitro Activation of the ovaries.
- Conditions
- Menopause, Menopause Ovarian Failure, Ovarian Failure, Premature Ovarian Failure
- Trial name
- SEGOVA (NCT04009473)
- Testing
- SEGOVA procedure
- Where
- 3 sites in Malta, North Macedonia and 1 more
- Volunteers
- 100 people
- Sponsor
- Forever Young d.o.o.
Multiple Myeloma
Preventive Treatment of VETD in Patients With Multiple Myeloma Receiving Chemotherapy With Thalidomide or Lenalinomide.
Patients with multiple myeloma have seen their survival rate strongly improved with the use of new anti angiogenic agents. Among them, the new chemotherapy with thalidomide or lenalinomide are frequently successfully suggested in…
- Trial name
- NCT01268774
- Volunteers
- 529 people
- Sponsor
- LEO Pharma
Chronic Myeloproliferative Disorders, Leukemia
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
RATIONALE: A peripheral stem cell transplant or an umbilical cord blood transplant from a donor may be able to replace blood-forming cells that were destroyed by chemotherapy or radiation therapy.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281879
- Testing
- anti-thymocyte globulin, filgrastim, busulfan
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- OHSU Knight Cancer Institute
Immune-related Adverse Event
Pharmacokinetic Study of Therapeutic Plasma Exchange
The purpose of this study is to characterize the pharmacokinetics of one or more ICIs during and after TPE/PLEX in patients with severe irAEs.
- Trial name
- NCT07756242
- Testing
- Spectra Optia Apheresis System
- Where
- United States
- Sponsor
- University of Chicago
Cancer
Prospective Collection of Tumor Biopsy and Plasma Samples From Cancer Patients Treated With Molecular Targeted Therapies or Immunotherapy
The purpose of this study is to collect blood samples, as well as tumor tissue for genetic analysis. The collection of samples will allow the creation of a plasma bank.
- Trial name
- Plasma-Target (NCT03835520)
- Testing
- Immunotherapeutic Agent, Molecular Target
- Where
- Belgium
- Volunteers
- 200 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Covid19
Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19
This protocol provides access to investigational convalescent plasma for hospitalized patients with COVID-19. Following provision of informed consent, patients will be administered around 500 mL of convalescent plasma obtained…
- Trial name
- Co-CLARITY (NCT04567173)
- Testing
- Anti-SARS-CoV-2 convalescent plasma
- Where
- Philippines
- Volunteers
- 44 people
- Sponsor
- University of the Philippines
Organophosphorus Poisoning
Fresh Frozen Plasma Transfusion in Acute Organophosphate Poisoning
this study clinical trial to assess the role of fresh frozen plasma as a novel available and easy to be applied rather than conventional therapy on organophosphate poisoned patients and prediction of it is prognosis on selected…
- Trial name
- NCT06256796
- Testing
- fresh frozen plasma
- Where
- Egypt
- Volunteers
- 92 people
- Sponsor
- Ain Shams University
Multiple Myeloma
A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma
The purpose of this study is to identify recommended Phase 3 doses (RP3D) for treatment combination (GR1803 injection plus anti-CD38 monoclonal antibody) and to characterize the efficacy of RP3D for the treatment combination.
- Trial name
- NCT07090954
- Testing
- GR1803 injection, Anti-CD38 Monoclonal Antibody
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma
Long-Term Follow-up Study
This is an observational, non-interventional, LTFS of investigational Caribou therapies in patients who have participated in a parent study: a prior Caribou-sponsored clinical study, special access program, or an IIT.
- Conditions
- Lymphoma, Non-Hodgkin, Relapsed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- LTFS (NCT05332054)
- Testing
- Caribou-sponsored investigational therapy
- Where
- 31 sites in United States
- Volunteers
- 150 people
- Sponsor
- Caribou Biosciences, Inc.
Multiple Myeloma
A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma
The purpose of this study was to determine clinical efficacy and safety of ruxolitinib (INCB018424), a small molecule Janus kinase 2 (JAK2)-inhibitor, in patients with refractory or relapsed multiple myeloma.
- Trial name
- NCT00639002
- Testing
- Ruxolitinib 25 mg, Dexamethasone 40 mg
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Incyte Corporation
Multiple Myeloma
Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy
The purpose of this study is to evaluate the tolerability, safety and the pharmacokinetic (PK) profile of daratumumab in Chinese participants with relapsed or refractory multiple myeloma (RRMM) who failed at least 2 prior lines…
- Trial name
- NCT02852837
- Testing
- Daratumumab
- Where
- 5 sites in China
- Volunteers
- 50 people
- Sponsor
- Janssen Research & Development, LLC
Respiratory Tract Diseases, Influenza (Pandemic)
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of hospitalised…
- Conditions
- Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia
- Trial name
- REMAP-CAP (NCT02735707)
- Testing
- Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide
- Where
- 408 sites in United States, Australia and 27 more
- Volunteers
- 20,000 people
- Sponsor
- UMC Utrecht
Multiple Myeloma (MM)
QLS4131 for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
This is a prospective, single-arm, phase II clinical trial evaluating the efficacy and safety of QLS4131 in patients with relapsed/refractory multiple myeloma (RRMM) with extramedullary disease (EMD).
- Trial name
- BEYOND-MM 002 (NCT07903636)
- Testing
- QLS4131
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Tendinopathy, Enthesopathy
Hyaluronic Acid Versus Platelet-Rich Plasma for Chronic Tendinopathy and Enthesopathy
Chronic tendinopathies and enthesopathies are common musculoskeletal conditions in orthopedics and sports medicine, frequently leading to pain, impaired function, and significantly reduced quality of life.
- Conditions
- Tendinopathy, Enthesopathy, Achilles Tendinopathy, Golfer's Elbow
- Trial name
- NCT07714811
- Testing
- Hyaluronic acid injection, Autologous Platelet-Rich Plasma Injection
- Where
- Poland
- Volunteers
- 80 people
- Sponsor
- Ortonika Orthopedic Medical Clinic in Lublin
Multiple Myeloma
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and…
- Trial name
- NCT02773030
- Testing
- CC-220, Dexamethasone, Daratumumab
- Where
- 162 sites in United States, Australia and 9 more
- Volunteers
- 466 people
- Sponsor
- Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.